PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31598169-6	2019	CMap analysis has identified that antipyrine, ondansetron, and econazole may be candidate targeted drugs for sarcoma patients with PVT1 overexpression.	Antipyrine	34-44	Pvt1 oncogene	Homo sapiens	131-135
27417180-5	2016	The CYP3A4 assay was evaluated using two long t1/2 compounds, carbamazepine and antipyrine (t1/2 > 30 minutes); one moderate t1/2 compound, ketoconazole (10 < t1/2 < 30 minutes); and two short t1/2 compounds, loperamide and buspirone (t1/2 < 10 minutes).	Antipyrine	80-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
26840714-11	2016	These results suggest that beta2-adrenoceptor activation occurred in delayed liquid gastric emptying induced by the phenylpyrazole derivatives dipyrone, 4-aminoantipyrine, and antipyrine.	Antipyrine	160-170	adrenoceptor beta 2	Rattus norvegicus	27-45
22186338-4	2012	The limits of detection and quantification were 3.2 and 9.7 mug mL-1 for diminazene diaceturate and 9.57 and 28.99 mug mL-1 for phenazone.	Antipyrine	128-137	L1 cell adhesion molecule	Mus musculus	119-123
22842351-2	2012	The antipyrine-phenylboronic acid 1b crystallizes in the monoclinic space group P2(1)/c, and displays an E configuration about the CN double bond.	Antipyrine	4-14	cyclin dependent kinase inhibitor 1A	Homo sapiens	80-87
25435228-3	2015	Under optimal experimental conditions (0.5 M sulfuric acid, 6x10(-3) M sodium nitrite, time 6 min) the absorbance of the colored extract at the 345 nm obeys Beer s law in the range of 3-200 muM of antipyrine in saliva.	Antipyrine	197-207	latexin	Homo sapiens	190-193
25435228-5	2015	The relative standard deviation for the determination of 50 muM antipyrine was 4.5% (n=10).	Antipyrine	64-74	latexin	Homo sapiens	60-63
17662339-3	2007	For phenazone and propyphenazone a complete biological transformation into their respective metabolites 1,5-dimethyl-1,2-dehydro-3-pyrazolone (DP) and 4-(2-methylethyl)-1,5-dimethyl-1,2-dehydro-3-pyrazolone (PDP) was observed.	Antipyrine	4-13	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	208-211
17662339-9	2007	The concentrations of the metabolites DP and PDP are even higher in the purified water than in the raw water caused by their formation during degradation of phenazone and propyphenazone.	Antipyrine	157-166	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	45-48
16674937-12	2006	The selective COX-3 inhibitors, aminopyrine and antipyrine also reduced writhing responses and brain PGE(2) biosynthesis.	Antipyrine	48-58	cytochrome c oxidase III, mitochondrial	Mus musculus	14-19
17628532-7	2007	Alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transferase values were significantly higher with significantly lower antipyrine clearance in Child-A, B, and C patients than in normal volunteers.	Antipyrine	142-152	glutamic--pyruvic transaminase	Homo sapiens	0-24
12630024-7	2003	Univariate analysis of the subgroup with antipyrine pharmacokinetic data revealed a significant relation between survival and baseline albumin (p = 0.039), total cholesterol (p = 0.036), AST (p = 0.017), log of total bilirubin (p = 0.017), and Child-Pugh class (p = 0.029), but not with parameters of antipyrine metabolism.	Antipyrine	41-51	solute carrier family 17 member 5	Homo sapiens	187-190
14570767-8	2003	Mechanism-based inhibition of CYP1A2 may explain why zileuton decreases the oral clearance of antipyrine, propranolol, (R)-warfarin, and theophylline, at doses that have a minimal effect on the pharmacokinetics of (S)-warfarin, phenytoin, and terfenadine.	Antipyrine	94-104	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	30-36
12698250-1	2003	OBJECTIVE: Antipyrine metabolism is a "gold standard" measure of mixed cytochrome P450 (CYP) mediated drug metabolism in humans.	Antipyrine	11-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-86
12698250-1	2003	OBJECTIVE: Antipyrine metabolism is a "gold standard" measure of mixed cytochrome P450 (CYP) mediated drug metabolism in humans.	Antipyrine	11-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-91
15659313-8	2005	When antipyrine was administered intravenously to wild-type mice and TNF-alpha-/- mice treated 24 h earlier with endotoxin, the plasma concentrations of antipyrine in TNF-alpha-/- mice 3 h after injection were significantly higher than those in wild-type mice.	Antipyrine	5-15	tumor necrosis factor	Mus musculus	69-78
15659313-8	2005	When antipyrine was administered intravenously to wild-type mice and TNF-alpha-/- mice treated 24 h earlier with endotoxin, the plasma concentrations of antipyrine in TNF-alpha-/- mice 3 h after injection were significantly higher than those in wild-type mice.	Antipyrine	5-15	tumor necrosis factor	Mus musculus	167-176
15659313-8	2005	When antipyrine was administered intravenously to wild-type mice and TNF-alpha-/- mice treated 24 h earlier with endotoxin, the plasma concentrations of antipyrine in TNF-alpha-/- mice 3 h after injection were significantly higher than those in wild-type mice.	Antipyrine	153-163	tumor necrosis factor	Mus musculus	69-78
15659313-8	2005	When antipyrine was administered intravenously to wild-type mice and TNF-alpha-/- mice treated 24 h earlier with endotoxin, the plasma concentrations of antipyrine in TNF-alpha-/- mice 3 h after injection were significantly higher than those in wild-type mice.	Antipyrine	153-163	tumor necrosis factor	Mus musculus	167-176
11956503-4	2002	CYP enzyme activities were measured by means of the metabolic ratios of sparteine (CYP2D6), endogenous cortisol metabolism (CYP3A4), and caffeine (CYP1A2), as well as by the S/R ratio of mephenytoin (CYP2C19) and antipyrine clearance.	Antipyrine	213-223	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
12242329-12	2002	Comparison of canine COX-3 activity with murine COX-1 and -2 demonstrates that this enzyme is selectively inhibited by analgesic/antipyretic drugs such as acetaminophen, phenacetin, antipyrine, and dipyrone, and is potently inhibited by some nonsteroidal antiinflammatory drugs.	Antipyrine	182-192	cytochrome c oxidase subunit III	Canis lupus familiaris	21-26
12242329-12	2002	Comparison of canine COX-3 activity with murine COX-1 and -2 demonstrates that this enzyme is selectively inhibited by analgesic/antipyretic drugs such as acetaminophen, phenacetin, antipyrine, and dipyrone, and is potently inhibited by some nonsteroidal antiinflammatory drugs.	Antipyrine	182-192	cytochrome c oxidase I, mitochondrial	Mus musculus	48-60
11735098-5	2001	Furthermore, antipyrine reacts quickly with hydroxyl radicals (10(10)-10(11) L x mol(-1) x s(-1)) to form para- and ortho-hydroxyantipyrine (o-APOH).	Antipyrine	13-23	apolipoprotein H	Homo sapiens	143-147
11847531-0	2002	Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.	Antipyrine	60-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	Antipyrine	202-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
11847531-1	2002	The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug.	Antipyrine	202-212	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-69
11847531-9	2002	Since the CL(T) of antipyrine is a general measure of CYP enzymes but with a slight to moderate weight toward CYP1A2, we suggest the involvement of this enzyme in ASOX to ASON metabolism in man.	Antipyrine	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-57
11847531-9	2002	Since the CL(T) of antipyrine is a general measure of CYP enzymes but with a slight to moderate weight toward CYP1A2, we suggest the involvement of this enzyme in ASOX to ASON metabolism in man.	Antipyrine	19-29	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	110-116
11735098-9	2001	Exercise significantly increased the ratio of para-hydroxyantipyrine (p-APOH) to native antipyrine in plasma (.0014 +/-.0001 v.0021 +/-.0002; P <.0001).	Antipyrine	58-68	apolipoprotein H	Homo sapiens	72-76
11785906-9	2001	According to the data obtained with microsomes from uninduced rat livers, the formation of the three major metabolites of antipyrine is extensively mediated by CYP2C11/C6.	Antipyrine	122-132	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	160-167
11124226-9	2001	In addition, our results suggest CYP1A2 inhibition as the mechanism behind the observed thiabendazole/theophylline and primaquine/antipyrine interactions in vivo.	Antipyrine	130-140	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	33-39
11785906-10	2001	In microsomes from induced animal liver, CYP2B and CYP3A may contribute to both N-demethylation and 4-hydroxylation of antipyrine.	Antipyrine	119-129	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	51-56
10725303-2	2000	We previously showed that liver volume normalized to body weight was inversely related to age, but that the systemic clearance of a nonspecific cytochrome P450 (CYP) substrate (antipyrine) was higher in young children compared with adults even when normalized per liver volume.	Antipyrine	177-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	144-159
10725303-2	2000	We previously showed that liver volume normalized to body weight was inversely related to age, but that the systemic clearance of a nonspecific cytochrome P450 (CYP) substrate (antipyrine) was higher in young children compared with adults even when normalized per liver volume.	Antipyrine	177-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-164
9840137-8	1998	Plasma fibronectin displayed a positive correlation with antipyrine metabolism and parameters of hepatic synthesis.	Antipyrine	57-67	fibronectin 1	Homo sapiens	7-18
10616961-5	1999	Results indicated that CCl4 significantly increased the elimination half-life (t(1/2)) of antipyrine from 2.59 +/- 1.04 to 11.25 +/- 3.91 h (P < 0.001) and decreased its clearance (CL) from 65.94 to 10.84 ml/h as compared to control.	Antipyrine	90-100	C-C motif chemokine ligand 4	Rattus norvegicus	23-27
10809177-10	2000	The corresponding values for unbound intrinsic clearances (CLu,int) for antipyrine, ethanol, lidocaine and oxygen were: 1.6, 31.0, 158.0 and 27.5 ml/min, respectively.	Antipyrine	72-82	clusterin	Rattus norvegicus	59-62
9612607-9	1998	In contrast to these results, we found a significant decrease in IFN-alpha and IFN-gamma (19.8 +/- 3.6 U/ml, 4.6 +/- 1.5 U/ml before; 7.9 +/- 2.6 U/ml, 1.9 +/- 1.3 U/ml after administration of ZDV), a decrease in antipyrine half-life, an elevation of the antipyrine clearance (49.8 +/- 15.7 ml/min, 57.3 +/- 13.7 ml/min) and an elevation of the clearances to metabolite.	Antipyrine	213-223	interferon alpha 1	Homo sapiens	65-74
9612607-9	1998	In contrast to these results, we found a significant decrease in IFN-alpha and IFN-gamma (19.8 +/- 3.6 U/ml, 4.6 +/- 1.5 U/ml before; 7.9 +/- 2.6 U/ml, 1.9 +/- 1.3 U/ml after administration of ZDV), a decrease in antipyrine half-life, an elevation of the antipyrine clearance (49.8 +/- 15.7 ml/min, 57.3 +/- 13.7 ml/min) and an elevation of the clearances to metabolite.	Antipyrine	213-223	interferon gamma	Homo sapiens	79-88
9091249-5	1997	The antipyrine (phenazone) clearance rate in young subjects was 46.4 +/- 18.5 ml.min-1, remained unaltered during the fourth decade, and declined after 40 years by a rate of 0.34 ml.min-1 per year toward old age (-29%, p < 0.001).	Antipyrine	4-14	CD59 molecule (CD59 blood group)	Homo sapiens	81-86
9113263-5	1997	The addition of the cytochrome P-450 inhibitor, cimetidine, significantly reduced the amount of acetaldehyde accumulating from ethanol when hepatocytes were incubated with either antipyrine or aminopyrine.	Antipyrine	179-189	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	20-36
9113263-9	1997	The results suggest that cytochrome P-450-generated metabolites of antipyrine and aminopyrine cause an inhibition of the low K(m) mitochondrial aldehyde dehydrogenase and thus an accumulation of acetaldehyde from ethanol.	Antipyrine	67-77	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	25-41
9113263-9	1997	The results suggest that cytochrome P-450-generated metabolites of antipyrine and aminopyrine cause an inhibition of the low K(m) mitochondrial aldehyde dehydrogenase and thus an accumulation of acetaldehyde from ethanol.	Antipyrine	67-77	aldehyde dehydrogenase 2 family member	Rattus norvegicus	130-166
9091249-5	1997	The antipyrine (phenazone) clearance rate in young subjects was 46.4 +/- 18.5 ml.min-1, remained unaltered during the fourth decade, and declined after 40 years by a rate of 0.34 ml.min-1 per year toward old age (-29%, p < 0.001).	Antipyrine	4-14	CD59 molecule (CD59 blood group)	Homo sapiens	182-187
8049635-2	1994	Debrisoquine metabolism is controlled by a cytochrome P-450 isozyme encoded at the CYP2D6 locus, which is inducible by antipyrine and rifampicin.	Antipyrine	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
7602731-8	1994	RESULTS: Mean CLAP was increased by 61% (0.66 +/- 0.06 mL/min.kg-1 body wt vs 0.41 +/- 0.05 mL/min.kg-1 body wt in the preoperative period; p < .001), and antipyrine half-life was reduced by 42% (10.9 +/- 1.0 hours vs 18.9 +/- 2.0 hours; p < .001) after 5 days of hypocaloric peripheral parenteral nutrition.	Antipyrine	158-168	BCL10 immune signaling adaptor	Homo sapiens	14-18
8049635-2	1994	Debrisoquine metabolism is controlled by a cytochrome P-450 isozyme encoded at the CYP2D6 locus, which is inducible by antipyrine and rifampicin.	Antipyrine	119-129	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	83-89
8491059-12	1993	A highly significant correlation (p < 0.001) was found between phenazone clearance and the prothrombin time, albumin, gamma-globulin, factor V, antithrombin III, fibrinogen and total bilirubin.	Antipyrine	66-75	serpin family C member 1	Homo sapiens	147-163
9114909-2	1993	The influence of interferon-alpha (IFN alpha) on the clearances of theophylline (TH), antipyrine (AP) and hexobarbitone (HB) was studied in seven cancer patients given IFN alpha as their only treatment.	Antipyrine	86-96	interferon alpha 1	Homo sapiens	35-44
8491059-12	1993	A highly significant correlation (p < 0.001) was found between phenazone clearance and the prothrombin time, albumin, gamma-globulin, factor V, antithrombin III, fibrinogen and total bilirubin.	Antipyrine	66-75	fibrinogen beta chain	Homo sapiens	165-175
1909273-6	1991	During 8-39 (median 19) months of observation of 16 untreated patients, there was a significant fall in antipyrine clearance (Cl-Ap) but no change in serum albumin.	Antipyrine	104-114	selectin P ligand	Homo sapiens	126-131
1473785-2	1992	The cytochrome P-450-inducing capacity of isolated intact broccoli glucosinolates and their degradation products, resulting from myrosinase-catalysed hydrolysis, has been assessed in studies of the metabolism of antipyrine (AP) and metronidazole (MZ) in the rat.	Antipyrine	212-222	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	4-20
8447150-9	1993	The present results suggest that the P450 enzymes involved in antipyrine metabolism are differentially affected in cirrhosis, but there appear to be no differences in the activity of the enzymes between alcoholic and non-alcoholic cirrhosis.	Antipyrine	62-72	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	37-41
1786835-1	1991	Three and ten days after the administration of CCl4 (subcutaneously, once, 4 ml/kg of 50% oil solution) there were found a decrease of the rate of antipyrine elimination (intravenously, 50 mg/kg) from the blood plasma, an increase of the total bilirubin content, ALT activity and stimulation of lipid peroxidation processes.	Antipyrine	147-157	C-C motif chemokine 4	Oryctolagus cuniculus	47-51
2054276-4	1991	The formation clearance of antipyrine to 4-hydroxyantipyrine was decreased significantly from 10.8 +/- 2.7 to 6.6 +/- 2.7 ml min-1 (P less than 0.05), while that to 3-hydroxymethylantipyrine and norantipyrine was not altered by diltiazem.	Antipyrine	27-37	CD59 molecule (CD59 blood group)	Homo sapiens	125-130
2023880-1	1991	We describe a simplified and rapid liquid chromatographic determination of antipyrine clearance (CLAP) calculated from peak height ratios of drug/internal standard.	Antipyrine	75-85	BCL10 immune signaling adaptor	Homo sapiens	97-101
2343186-0	1990	Evaluation of cytochrome P-450 mediated metabolism of antipyrine in the rat at different extents of fluosol-DA hemodilution.	Antipyrine	54-64	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	14-30
2256435-2	1990	Antipyrine is a useful marker drug for cytochrome P-450 dependent hepatic drug metabolism.	Antipyrine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-55
2342384-1	1990	The influence of ageing on the metabolism of antipyrine by different forms of cytochrome P-450 was studied in vitro, by measuring the formation of antipyrine metabolites by microsomes isolated from untreated rats, which were grouped into 5 different ages.	Antipyrine	45-55	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	78-94
1977543-5	1990	Antipyrine and phenobarbital increased antipyrine elimination, serum gamma-glutamyltransferase, and the urinary excretion of renal gamma-glutamyltransferase, whereas urinary beta-N-acetylglucosaminidase, beta-glucuronidase, and total protein and glucose excretion were unchanged.	Antipyrine	0-10	glucuronidase beta	Homo sapiens	204-222
2097286-3	1990	The objective of this work was to quantitate the effects of low environmental levels of the contaminant and enzyme inducer (PCB) on the pharmacokinetics of antipyrine, a drug whose primary elimination route is liver metabolism.	Antipyrine	156-166	pyruvate carboxylase	Rattus norvegicus	124-127
2896083-6	1988	Antipyrine plasma clearance and 6-beta-OHF excretion rates increased significantly in the groups treated with antipyrine or rifampicin, while serum GGT activities were enhanced only following antipyrine.	Antipyrine	192-202	gamma-glutamyltransferase light chain family member 3	Homo sapiens	148-151
2697484-10	1989	The hyperglycemic patients treated with insulin showed improved glucose metabolism, an improved C-peptide response and antipyrine metabolism.	Antipyrine	119-129	insulin	Homo sapiens	40-47
3243660-6	1988	Since many drugs are metabolized by cytochrome P-450, similar to phenazone, it is likely that their elimination in patients with Hodgkin"s disease and in patients with non-Hodgkin"s lymphoma will be also changed.	Antipyrine	65-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-52
3171600-1	1988	To verify the potential in vivo inhibitory effect on liver function of tumor necrosis factor (TNF), also known as cachectin, antipyrine and diazepam were chosen to probe the hepatic mixed-function oxidase system.	Antipyrine	125-135	tumor necrosis factor-like	Rattus norvegicus	94-97
3171600-3	1988	This was probably due to a decrease in hepatic cytochrome P-450 activities that are responsible for antipyrine and diazepam metabolism in TNF-treated rats.	Antipyrine	100-110	tumor necrosis factor-like	Rattus norvegicus	138-141
2896083-7	1988	Antipyrine administration increased urinary GGT excretion both immediately and one week after cessation of drug administration, but no changes were found following the administration of rifampicin.	Antipyrine	0-10	gamma-glutamyltransferase light chain family member 3	Homo sapiens	44-47
2896083-9	1988	Based on these findings, the increased urinary GGT excretion observed following antipyrine treatment may be due to an inducing effect on the renal tubular cells, as no evidence for a toxic renal damage was found.	Antipyrine	80-90	gamma-glutamyltransferase light chain family member 3	Homo sapiens	47-50
3798958-1	1986	The effect of three inducers of cytochrome P-450-mediated drug oxidations (Pregnenolone carbonitrile, promethazine and antipyrine) on antipyrine metabolite kinetics has been investigated using the urinary metabolite pattern and 14CO2 exhalation rate (CER)-time profile following [N-methyl-14C]antipyrine administration.	Antipyrine	119-129	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	32-48
2894017-0	1987	[Effect of somatostatin on the biological availability of phenazone in healthy men].	Antipyrine	58-67	somatostatin	Homo sapiens	11-23
3383988-11	1988	The two main inferences are first, that tolbutamide and antipyrine are metabolised by different forms of cytochrome P-450, and second that a battery of model substrates is needed to investigate the inhibitory effects of a drug in man.	Antipyrine	56-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121
2440440-1	1987	We investigated the role played by monoclonal antibody defined classes of cytochrome P-450 in the metabolism of antipyrine, aminopyrine and theophylline.	Antipyrine	112-122	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	74-90
4029252-3	1985	In all patients the oxidative cytochrome P-450 dependent drug metabolism was induced as shown by an increase of antipyrine-clearance from 36.3 +/- 8.8 to 80.6 +/- 20.1 ml/min and an enhanced urinary excretion of 6-beta-hydroxycortisol from 454 +/- 1.99 to 1607 +/- 362 micrograms/24 h. Furthermore, in all 6 patients the serum alkaline phosphatase declined.	Antipyrine	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-46
6508979-7	1984	This provides further evidence for the involvement of different iso-enzymes of the cytochrome P-450 system in antipyrine metabolism in man.	Antipyrine	110-120	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-99
2858532-6	1985	The results suggest that not all benzimidazoles inhibit hepatic drug metabolizing enzymes and that different forms of cytochrome P-450 are involved in the metabolism of antipyrine and tolbutamide.	Antipyrine	169-179	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	118-134
7450397-1	1981	The aim of this study was to look for correlations between the metabolic clearance rate of antipyrine and (a) the concentration of cytochrome P-450, and (b) the NADPH cytochrome c reductase, aminopyrine demethylase, and aniline hydroxylase activities in the liver microsomes of 20 patients without liver diseases.	Antipyrine	91-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-147
6508979-5	1984	Rifampicin seems to induce preferentially the cytochrome P-450 (iso-) enzyme(s) involved in the demethylation of antipyrine to norantipyrine.	Antipyrine	113-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
6734034-7	1984	Antipyrine Clsal and Clm correlated to theophylline Clp (r between 0.50 and 0.69).	Antipyrine	0-10	calmodulin like 3	Homo sapiens	52-55
6381341-2	1983	In humans, troleandomycin also induces microsomal enzymes, and forms an inactive cytochrome P-450-troleandomycin metabolite complex; the clearance of antipyrine, that of theophylline, and that of methylprednisolone are markedly reduced.	Antipyrine	150-160	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	81-97
7056021-2	1982	The in vivo metabolism of antipyrine, which is also catalyzed by microsomal cytochrome P-450-dependent monooxygenases, has been reported to be correlated with AHH inducibility in human lymphocytes.	Antipyrine	26-36	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	159-162
6946467-4	1981	These results suggest that each molecular form of cytochrome P-450 that converts antipyrine to a different metabolite exhibits genetically controlled interindividual variations in activity.	Antipyrine	81-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-66
7341283-9	1981	It is concluded that this provides evidence for the involvement of at least two different forms of cytochrome P-450 in antipyrine metabolism in man.	Antipyrine	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	99-115
6744489-2	1984	Effect of bovine serum albumin on the color reaction of xanthurenic acid with 4-aminoantipyrine--inhibition of antipyrine red production by bovine serum albumin.	Antipyrine	85-95	albumin	Homo sapiens	17-30
6744489-2	1984	Effect of bovine serum albumin on the color reaction of xanthurenic acid with 4-aminoantipyrine--inhibition of antipyrine red production by bovine serum albumin.	Antipyrine	85-95	albumin	Homo sapiens	147-160
6328898-2	1984	The role of glucose-6-phosphatase (G6Pase) in postreceptional glucose handling in non-insulin dependent diabetics ( NIDDs ) was in investigated by comparing the enzyme values in diagnostic liver biopsy samples with fasting blood glucose (BG), immunoreactive insulin (IRI) and plasma antipyrine half-life (T/2).	Antipyrine	283-293	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	35-41
6636196-5	1983	Cytochrome P-450 isozymes, purified from xylene- and phenobarbital-treated animals, were efficient catalysts of antipyrine metabolism, with turnover numbers of 33.3 and 21.1, respectively.	Antipyrine	112-122	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-16
6860533-4	1983	It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin.	Antipyrine	266-276	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	86-102
6220203-4	1983	Two compounds, acetanilide and antipyrine, for which the in vivo evidence was against an association between their metabolism and that of debrisoquine, were weak, noncompetitive inhibitors of debrisoquine 4-hydroxylase activity.	Antipyrine	31-41	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	192-218
7267701-6	1981	It is concluded that different species of the drug-oxidizing enzymes (cytochrome P-450 system) are involved in the metabolism of debrisoquine and antipyrine.	Antipyrine	146-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
234834-0	1975	Correlation of aryl hydrocarbon hydroxylase activity of human lymphocyte cultures and plasma elimination rates for antipyrine and phenylbutazone.	Antipyrine	115-125	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	15-43
234834-1	1975	A high correlation was observed between the aryl hydrocarbon hydroxylase activities in short-term lymphocyte cultures of 23 individuals and their plasma half-lives of antipyrine and phenylbutazone.	Antipyrine	167-177	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	44-72
234834-2	1975	Individuals with low inducibility of aryl hydrocarbon hydroxylase activities had very long plasma half-lives of antipyrine and phenylbutazone, whereas subjects with high inducibility of aryl hydrocarbon hydroxylase activites had relatively short plasma half-lives.	Antipyrine	112-122	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	37-65
4405530-1	1973	A significant rise in plasma gamma-glutamyl transpeptidase activity (GGT) was observed on 13 out of 14 occasions on which patients on long-term treatment with the oral anticoagulant warfarin were given amylobarbitone, quinalbarbitone, or phenazone (antipyrine) for 30 days.	Antipyrine	238-247	inactive glutathione hydrolase 2	Homo sapiens	29-58
4405530-1	1973	A significant rise in plasma gamma-glutamyl transpeptidase activity (GGT) was observed on 13 out of 14 occasions on which patients on long-term treatment with the oral anticoagulant warfarin were given amylobarbitone, quinalbarbitone, or phenazone (antipyrine) for 30 days.	Antipyrine	249-259	inactive glutathione hydrolase 2	Homo sapiens	29-58
18150766-0	1949	Influence of antipyrine on respiration, glycolysis and cholinesterase activity in rat brain.	Antipyrine	13-23	butyrylcholinesterase	Rattus norvegicus	55-69
34042935-1	2021	A Pd(ii)-catalyzed direct functionalization reaction of the 4Csp2-H bond of antipyrine derivatives is reported.	Antipyrine	76-86	regulator of calcineurin 2	Homo sapiens	61-65
33985510-7	2021	Using the TCGA AML dataset, we also identified four drugs (phenazone, benzydamine, cinnarizine, antazoline) that may serve as SRP14-targeted drugs in AML.	Antipyrine	59-68	signal recognition particle 14	Homo sapiens	126-131
7357559-7	1980	Furthermore, the data also indicated a good negative correlation between AHH inducibility and the measurements of plasma antipyrine or urinary 4-hydroxyantipyrine half-lives (r = -0.88 or -0.91), respectively.	Antipyrine	121-131	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	73-76
506875-0	1979	The effect of carbon tetrachloride (CCl4) induced liver damage on the volume of distribution, the elimination half-life and body clearance of antipyrine and warfarin in rabbits.	Antipyrine	142-152	C-C motif chemokine 4	Oryctolagus cuniculus	36-40
14404248-0	1959	[The determination of antipyrine and caffeine in the presence of phenacetin with the aid of ion exchange resins].	Antipyrine	22-32	activation induced cytidine deaminase	Homo sapiens	85-88